Daiwa Securities Group Inc. Pro Qr Therapeutics N.V. Transaction History

Daiwa Securities Group Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$0.56 - $1.0 $10,454 - $18,669	-18,669 Reduced 98.9%	208 $0
Q1 2022 Apr 29, 2022	BUY	$0.9 - $8.39 $5,274 - $49,165	5,860 Added 45.02%	18,877 $17,000
Q4 2021 Feb 03, 2022	BUY	$6.58 - $8.44 $15,476 - $19,850	2,352 Added 22.05%	13,017 $104,000
Q3 2021 Nov 05, 2021	BUY	$5.16 - $8.47 $55,031 - $90,332	10,665 New	10,665 $89,000
Q4 2020 Feb 04, 2021	SELL	$3.58 - $4.85 $880 - $1,193	-246 Closed	0 $0
Q1 2019 Apr 26, 2019	SELL	$12.5 - $18.48 $1,300 - $1,921	-104 Reduced 29.71%	246 $3,000
Q4 2018 Feb 05, 2019	BUY	$15.25 - $22.4 $5,337 - $7,839	350 New	350 $6,000

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $188M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.